ClinicalTrials.gg
Active, not recruitingNCT04510740JADEUpdated Nov 5, 2026

Liver Cancer Registry Platform

An observational study in Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma, sponsored by iOMEDICO AG. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by iOMEDICO AG · Observational

How we know

Updated Nov 5, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Carcinoma, Hepatocellular with a site in Germany — 23 open to participants now, 38 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Germany.

Planned enrollment
4th of 25
1,000 · median 250
Started
2020
with 6 others
Observational
25 of 149
5 open now
Primary completion
2026-10
later than 11 of 37 live
Registered
109th of 149
by date

Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, this one is the 4th largest by planned enrollment of the 25 observational ones that give a count, is one of 7 that started in 2020, is one of 25 observational ones, reaches primary completion later than 11 of the 37 other live ones, and was the 109th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

23 of the 149 studies in Carcinoma, Hepatocellular with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Carcinoma, Hepatocellular with a site in Germany, or all of them as a file.
02

Study summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.

Read the detailed description

JADE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of HCC or CCC in Germany. The registry will follow patients for up to three years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

Health-related quality of life in patients with HCC / CCC will be evaluated for up to three years.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
  • Cholangiocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with hepatocellular carcinoma (HCC), or cholangiocarcinoma (CCC) starting treatment for early, intermediate or advanced disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced/ stage
  • Age ≥ 18 years
  • Signed and dated (IC):

    • For participation in the PRO module: Before primary locoregional therapy or start of first systemic treatment
    • For no participation in the PRO module: No later than 8 weeks after primary locoregional therapy or start of first systemic treatment

Exclusion criteria

Exclusion criteria:

Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Hepatocellular Carcinoma (HCC)

    Patients with Hepatocellular Carcinoma (HCC)

    Other: Physician's choice according to patient's needs.

  • Cholangiocarcinoma (CCC)

    Patients with Cholangiocarcinoma (CCC)

    Other: Physician's choice according to patient's needs.

Interventions

  • OtherPhysician's choice according to patient's needs.

    Routine care as per site standard.

06

What researchers measure

Primary outcomes

  1. Course of treatment (treatment reality).

    Documentation of anamnestic data and therapy sequences.

    Time frame: 3 years per patient.

Secondary outcomes

  1. Best Response.

    Documentation of response rates per line of treatment.

    Time frame: 3 years per patient.

  2. Progression-free survival.

    Documentation of progression-free survival per line of treatment.

    Time frame: 3 years per patient.

  3. Overall survival.

    Documentation of overall survival per line of treatment.

    Time frame: 3 years per patient.

  4. Health-related quality of life (Patient-reported outcome, PRO).

    EORTC QLQ-C30 core questionnaire \[European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high scale score represents a higher response level: (a) global health status: a high score represents high quality of life, (b) functional scales: a high score represents high/healthy level of functioning, (c) symptom scales/items: a high score represents high level of symptomatology or problems\]

    Time frame: 3 years per patient.

  5. Carcinoma Health-related quality of life (Patient-reported outcome, PRO).

    EORTC QLQ-HCC18, the hepatocellular carcinoma specific module / EORTC QLQ-BIL21, the cholangiocarcinoma specific module \[European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high score for scales and single items represents a high level of symptomatology or problems\].

    Time frame: 3 years per patient.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2026, 74 months.

Of 49 industry-sponsored observational studies under Carcinoma, Hepatocellular, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's 74 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2020
First posted
Aug 12, 2020
StartActual
Aug 9, 2020
Primary completionActual
Oct 21, 2026was Sep 2026
CompletionEst.
Dec 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Oct 21, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Sep 2026→Oct 21, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04510740
Lead sponsor
iOMEDICO AG
Responsible party
Sponsor
First posted
Aug 12, 2020
Start date
Aug 9, 2020
Primary completion
Oct 21, 2026
Completion
Dec 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Thomas Berg, Prof.Dr.
study chair · Leipzig
Peter R. Galle, Prof.Dr.
study chair · Mainz
Wolf P. Hofmann, Prof.Dr.
study chair · Berlin
Achim Kautz
study chair · Köln
Philippe Pereira, Prof.Dr.
study chair · Heilbronn
Karin Potthoff, Dr.
study chair · Freiburg im Breisgau
Jan Schröder, PD Dr.
study chair · Mülheim an der Ruhr
Robert Thimme, Prof.Dr.
study chair · Freiburg im Breisgau

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion